Skip to contentM
Marker Therapeutics, Inc.
M
MRKRMarker Therapeutics, Inc. Q2 2023 · 10-Q
Revenue$762.66K$762.66K−3.5% vs Q2 2022 Net Income$2.52M$2.52MN/M vs Q2 2022 EPS Diluted$0.29$0.29N/M vs Q2 2022 Operating Income-$4,134,060N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-542.1%+124.4 pt vs Q2 2022
Net margin329.9%+1499.3 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 14, 2023 · 45 d after period end